BeOne Medicines (ONC)

Executive Summary

BeOne Medicines (BeiGene) is a global oncology-focused biotechnology company with a robust portfolio of approved therapies and an extensive pipeline. The company's two lead products, BRUKINSA® (zanubrutinib) and tislelizumab, have been approved in multiple markets for various hematologic and solid tumor indications. With over 10,000 employees and a global commercial footprint, BeOne is well-positioned to expand its market share. The company's pipeline includes numerous early- and mid-stage candidates targeting B-cell malignancies, solid tumors, and autoimmune diseases, leveraging modalities such as small molecules, antibodies, and combination therapies. Significant manufacturing capabilities in China and the U.S. support its integrated supply chain. BeOne's strategic focus on innovation and global expansion underpins its growth trajectory. The company is advancing several key programs, including sonrotoclax (BCL-2 inhibitor) and BGB-16673 (BTK degrader), which could address significant unmet needs. Recent pipeline updates indicate a shift towards combination regimens and next-generation therapies. With a strong cash position and a track record of regulatory success, BeOne is poised to deliver value through both commercial execution and clinical milestones. The company's conviction score of 85 reflects its solid foundation and promising pipeline, though competition and regulatory risks remain.

Upcoming Catalysts (preview)

• Q3 2026Tislelizumab potential FDA approval in 1L ESCC70% success
• Q4 2026Zanubrutinib Phase 3 ALPINE update in CLL/SLL90% success
• H2 2026Sonrotoclax Phase 1/2 data in hematologic malignancies60% success